<DOC>
	<DOCNO>NCT01181999</DOCNO>
	<brief_summary>Rituximab ( R ) plus CHOP ( cyclophosphamide , doxorubicin , vincristine , prednisolone ) combination consider new gold standard first-line treatment elderly patient diffuse large B-cell lymphoma ( DLBCL ) . The study aim evaluate overall response rate safety four cycle R-CHOP chemotherapy follow rituximab augmentation ( weekly four time infusion ) newly diagnose DLBCL patient age 70 year .</brief_summary>
	<brief_title>Rituximab Augmentation Following R-CHOP Induction Chemotherapy Extremely Elderly Patients With Diffuse Large B Cell Lymphoma</brief_title>
	<detailed_description>1 . Four cycle R-CHOP chemotherapy induction treatment [ Dose intensity CHOP chemotherapy modulate accord Charlson Comorbidity Index ( CCI ) ] If patient CCI &lt; 1 - Rituximab : 375 mg/m2 , day 1 every 3 week . - Conventional dose CHOP chemotherapy repeat every 3 week . If patient CCI ≥1 - Rituximab : 375 mg/m2 , day 1 every 3 week . - 75 % conventional CHOP repeat every 3 week . 2 . Rituximab augmentation - Rituximab : 375 mg/m2 , every week x 4 time . - Trimethoprim-sulfamethoxazole 1 tablet per day augmentation</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1 . Histologically confirm CD20 positive DLBCL 2 . Age ≥ 70 3 . Ann Arbor stage II , III IV 4 . No prior chemotherapy radiotherapy DLBCL 5 . Performance status ( Eastern Cooperative Oncology Group ) ≤ 2 6 . At least one bidimensionally measurable lesion ( ) ≥ 2 cm conventional computerize tomography ( CT ) ≥ 1 cm spiral CT skin lesion ( photograph take ) ≥ 2 cm measurable lesion physical examination ≥ 2 cm 7 . Cardiac ejection fraction ≥ 50 % measure echocardiogram without clinically significant abnormality 8 . Adequate renal function : serum creatinine level &lt; 2 mg/dL ( 177 μmol/L ) 9 . Adequate liver function : 10 . Adequate bone marrow function : hemoglobin ≥ 9 g/dL absolute neutrophil count ≥ 1,500/μL platelet count ≥ 75,000/μL , unless abnormality due bone marrow involvement lymphoma 11 . Life expectancy 6 month 12 . Informed consent 1 . Other subtypes nonHodgkin 's lymphoma 2 . Patients transform follicular lymphoma indolent lymphoma 3 . Primary Central Nervous System ( CNS ) DLBCL 4 . CNS involvement lymphoma evidence spinal cord compression . 5 . Patients known history human immunodeficiency virus ( HIV ) seropositivity hepatitis C virus ( + ) . 6 . Any malignancy within past 5 year except curatively treat nonmelanoma skin cancer situ carcinoma cervix uteri 7 . Pregnant lactate woman , woman childbearing potential employ adequate contraception 8 . Other serious illness medical condition</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>diffuse large B-cell lymphoma</keyword>
	<keyword>elderly patient</keyword>
	<keyword>rituximab augmentation</keyword>
</DOC>